Sakuma, S., Ishimura, M., Yuba, Y., Itoh, Y., & Fujimoto, Y
Direct vendors should use insulated, cold-safe packing and ensure quick US delivery
Representative domains include: Gastrointestinal and hepatic models: Protection against ulcers, leaky gut, IBSlike symptoms, Crohntype inflammation, and toxic liver injury (e.g., CCl4, NSAID, and alcohol models), with improved mucosal healing and barrier integrity
Weight loss trajectory was still accelerating Phase 1 (oral): 10.4-13.1% weight loss at 12 weeks depending on dosing regimen vs 1.2% placebo Phase 2 (T2D): SC amycretin showed up to 14.5% weight loss and HbA1c reductions up to 1.8% at 36 weeks
Preclinical research has demonstrated multiple effects of DSIP across various experimental models: Sleep Architecture Modifications Animal studies involving rodents and cats have shown that when DSIP is administered, there are significant changes in sleep-wake patterns